Gun Min Kim1, Sanghwa Kim2, Hyung Seok Park2, Jee Ye Kim2, Sanggen Nam2, Seho Park2, Seung Il Kim2, DoYoung Kim3, Joohyuk Sohn4. 1. Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-Ro, Seodaemun-Gu, Seoul, Korea. 2. Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. 3. Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea. 4. Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-Ro, Seodaemun-Gu, Seoul, Korea. oncosohn@yuhs.ac.
Abstract
PURPOSE: The purpose of this work is to determine the prevalence of chemotherapy-induced irreversible alopecia (CIIA), which is defined as an alopecia that exists at least 6 months after completion of chemotherapy and factors affecting CIIA in early breast cancer patients. METHODS: We performed a cross-sectional study. We retrospectively identified breast cancer patients who had received AC (Adriamycin, Cyclophosphamide) or AC-T (AC followed by Taxane) as neoadjuvant or adjuvant chemotherapy. We conducted questionnaire survey regarding alopecia and measured hair density using phototrichogram. RESULTS: From February 2015 to May 2015, among 265 patients who responded properly to the questionnaire, the women who answered they had severe alopecia (alopecia > 50% of scalp) were 19 patients (7.2%). AC-only and AC-T treated patients reported severe alopecia in 2.7% and 10.5%, respectively, which were significantly different (p < 0.001). Mean hair density was 75 hair/cm2 (range 42-112) and 75.2/cm2 (range 48.3-102) on occipital area and vertex area, respectively. Hair loss was the most frequent in parietal area (42.6%). Half of total patients (46%) and 73% of CIIA patients regarded that their hair became thinner after chemotherapy CONCLUSIONS: We found that significant proportion of early breast cancer patients were suffering from severe CIIA, especially when they had been treated with AC followed by taxane regimen.
PURPOSE: The purpose of this work is to determine the prevalence of chemotherapy-induced irreversible alopecia (CIIA), which is defined as an alopecia that exists at least 6 months after completion of chemotherapy and factors affecting CIIA in early breast cancerpatients. METHODS: We performed a cross-sectional study. We retrospectively identified breast cancerpatients who had received AC (Adriamycin, Cyclophosphamide) or AC-T (AC followed by Taxane) as neoadjuvant or adjuvant chemotherapy. We conducted questionnaire survey regarding alopecia and measured hair density using phototrichogram. RESULTS: From February 2015 to May 2015, among 265 patients who responded properly to the questionnaire, the women who answered they had severe alopecia (alopecia > 50% of scalp) were 19 patients (7.2%). AC-only and AC-T treated patients reported severe alopecia in 2.7% and 10.5%, respectively, which were significantly different (p < 0.001). Mean hair density was 75 hair/cm2 (range 42-112) and 75.2/cm2 (range 48.3-102) on occipital area and vertex area, respectively. Hair loss was the most frequent in parietal area (42.6%). Half of total patients (46%) and 73% of CIIA patients regarded that their hair became thinner after chemotherapy CONCLUSIONS: We found that significant proportion of early breast cancerpatients were suffering from severe CIIA, especially when they had been treated with AC followed by taxane regimen.
Entities:
Keywords:
Adverse reactions; Alopecia; Antineoplastic agents; Breast neoplasms; Drug-related side effects
Authors: Azael Freites-Martinez; Jerry Shapiro; Corina van den Hurk; Shari Goldfarb; Joaquin J Jimenez; Anthony M Rossi; Ralf Paus; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2018-04-14 Impact factor: 11.527
Authors: Rocío Núñez-Torres; Miguel Martín; Jose Ángel García-Sáenz; María Rodrigo-Faus; María Del Monte-Millán; Hugo Tejera-Pérez; Guillermo Pita; Julio C de la Torre-Montero; Karen Pinilla; Belén Herraez; Lorena Peiró-Chova; Begoña Bermejo; Anna Lluch; Anna González-Neira Journal: JAMA Dermatol Date: 2020-09-01 Impact factor: 10.282